Esperion reported a 35% to 38% increase in U.S. net product sales for 2025 compared to 2024, with total revenue expected to be $400 to $408 million. Cash and cash equivalents at year-end 2025 were $168 million. They anticipate operating expenses of $210 to $245 million for 2026. The company introduced Vision 2040 strategy focusing on global growth and expanding the pipeline. Their goal is to evolve into a global pharmaceutical company with multiple blockbuster products and a robust pipeline.

Esperion’s U.S. commercial strategy is focused on NEXLETOL and NEXLIZET, approved to prevent heart attacks and cardiovascular procedures. They’re expanding their market reach and developing new products to address unmet needs, including rare diseases. The company is also focusing on global expansion, with significant growth in Europe, Japan, and Canada. In the R&D pipeline, they have nominated ESP-2001 for preclinical development for primary sclerosing cholangitis. Financially, Esperion raised $75 million in 2025 and expects operating expenses of $210 to $245 million for 2026.

Read more at GlobeNewswire: Esperion Provides Business Update at 44th Annual J.P.